Triple Negative Breast Cancer Treatment Market Size, Share, Industry, Forecast and outlook (2024-2031)

Triple-Negative Breast Cancer Treatment Market is Segmented By Drug Type (Paclitaxel, Doxorubicin, Cyclophosphamide, Docetaxel, Carboplatin/Cisplatin, Others), By Distribution Channel (Hospitals, Cancer Research Institutes, Retail Clinics) and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031.

Report Overview

Triple Negative Breast Cancer Treatment Market is expected to reach at a CAGR of 8% during the forecast period (2024-2031).

Triple negative breast cancer (TNBC) is a rare cancer that affects about 13 in 100,000 women each year. It represents about 15 % of all invasive breast cancers. Triple negative breast cancer is one of three types of breast cancer.

Market Summary

To Get a Free Sample Click here

Market Dynamics

The global triple negative breast cancer treatment market growth is driven by the growing advancements in cancer research, rising prevalence of breast cancer and blood-related disorders among the growing population is surging demand for triple-negative breast cancer treatment solutions.

Strategic product launches by leading players is expected to drive the growth in the forecast period

According to the World Health Organization (WHO), cancer is the second-leading cause of death, globally - around 1 in 6 deaths is due to cancer, with an estimated 9.6 million deaths in 2018. WHO estimated around 2.09 million breast cancer cases were found worldwide. Industry players are focusing on expanding innovative products to get early market entry and a high triple-negative breast cancer treatment market share. Companies in the triple-negative breast cancer treatment market focus on improving their product offerings by entering into collaborations, acquisitions, and promotions. These key trends are being seen across North America, Europe, and Asian countries such as Malaysia, Japan, and China. Such strategies also enable companies to accelerate their market reach and revenue gain.

For instance, in November 2020, Roche partnered with the Government of Kenya to improve breast cancer care. This initiative was committed to expanding access to prevention and treatment services for women suffering from breast cancer.

Few side effects associated with the treatment is likely to hamper the market growth

Adverse reactions arising from breast cancer therapeutics, such as targeted therapies, may limit the market growth in the near future. For instance, according to the American Cancer Society (ACS), targeted therapies have several side effects, namely, skin problems, gastrointestinal problems such as diarrhea, and high blood pressure. In cases of severe adverse reactions, the patient may not be able to use that particular drug and may have to move toward other types of therapeutics. For instance, severe side effects of targeted therapy include rashes in several parts of the body and also the occurrence of blisters. Similarly, immunotherapy has side effects such as, fatigue, nausea. These adverse effects are likely to impede the market growth.

COVID-19 Impact Analysis

The COVID-19 pandemic has exhibited a short-term negative impact on the global triple-negative breast cancer treatment market, affecting manufacturing industries and oncology healthcare set-ups, leading to delay in diagnosis, postponement of routine screening, etc., to reduce time spent in hospitals to avoid the risk of infection. Increased funding from regional governments and leading companies for expansion of existing facilities and construction of new facilities is being done to tackle the COVID-19 pandemic. In addition, enhancing unique vaccine CDMO capabilities and capacity with technological advancements is a core strategy followed by leading CDMO players.

Market Segment Analysis

The paclitaxel segment is expected to hold the largest share in this market segment

Paclitaxel belongs to the group of medications known as antineoplastics and is used in the treatment of cancers. It works by inhibiting the growth of cancer cells and is used in the treatment of various cancers such as breast cancer, ovarian cancer, non-small cell lung cancer, etc. Fundamental advantages of paclitaxel injection involve quick outcomes, east accessibility, and better adequacy as well as accuracy.

Market Geographical Share

North America region holds the largest market share of global triple negative breast cancer treatment market

North America is a dominant region in the global triple-negative breast cancer treatment market in terms of revenue share. This reflects the increasing prevalence of cancer and rising number of trails for combination therapies to treat cancer in the region. According to the National Cancer Institute, in 2020, 1.8 million people will be diagnosed with cancer in the United States. An estimated 276,480 women and 2,620 men will be diagnosed with breast cancer, which makes it the most common cancer diagnosis.

Market Competitive Landscape

The global triple-negative breast cancer treatment market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include AstraZeneca PLC, Johnson & Johnson Services, Inc., Pfizer, Inc, F. Hoffman - La Roche Ltd, Bristol-Myers Squibb Company, Novartis AG, Mylan N.V, Eli Lilly and Company, Celgene Corporation and Sanofi S.A. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market. For instance, April 07, 2021, FDA approves Trodelvy, the First Treatment for Metastatic Triple-Negative Breast Cancer.

Key Companies to Watch

Novartis

Overview: Novartis AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland. It operates business through two divisions: Innovative medicine, Sandoz. Made up of two business units – Novartis Pharmaceuticals which includes Novartis Gene Therapies, and Novartis Oncology – Innovative Medicines Division commercializes innovative patented medicines to enhance health outcomes for patients and healthcare professionals. Sandoz is a global leader in generic pharmaceuticals and biosimilars that pioneers novel approaches to help people around the world access high-quality medicines.

Product Portfolio: It includes product like Piqray is a kinase inhibitor approved in combination with fulvestrant for the treatment of postmenopausal women, and men, with HR+/HER2-, PIK3CA-mutated, advanced or metastatic breast cancer.